Jean-Claude Souberbielle, Catherine Massart1, Sylvie Brailly-Tabard2, Catherine Cormier1, Etienne Cavalier1, Pierre Delanaye1, Philippe Chanson2. 1. Service des Explorations FonctionnellesNecker-Enfants Malades University Hospital, 149 Rue de Sèvres, Paris F75015, FranceHormonology LaboratoryPontchaillou University Hospital, Rennes F29000, FranceService de Génétique MoléculairePharmacogénétique et Hormonologie, F-94275 Le Kremlin-Bicêtre, FranceFaculté de Médecine Paris-SudUnité Mixte de Recherche-S1185, Univ Paris-Sud, Université Paris-Saclay, F-94276 Le Kremlin-Bicêtre, FranceInstitut National de la Santé et de la Recherche Médicale (INSERM) U1185F-94276 Le Kremlin-Bicêtre, FranceRheumatology DepartmentCochin University Hospital, Paris F75014, FranceClinical Chemistry DepartmentSart Tilman University Hospital, Liège, BelgiumNephrology and Dialysis DepartmentSart Tilman University Hospital, Liège, BelgiumAssistance Publique-Hôpitaux de ParisHôpital de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction and Centre de Référence des Maladies Endocriniennes Rares de la Croissance, F94275 Le Kremlin-Bicêtre, FranceUMR S1185Faculté de Médecine Paris-Sud, Univ Paris-Sud, Université Paris-Saclay, F-94276 Le Kremlin-Bicêtre, FranceINSERM U1185F-94276 Le Kremlin-Bicêtre, France. 2. Service des Explorations FonctionnellesNecker-Enfants Malades University Hospital, 149 Rue de Sèvres, Paris F75015, FranceHormonology LaboratoryPontchaillou University Hospital, Rennes F29000, FranceService de Génétique MoléculairePharmacogénétique et Hormonologie, F-94275 Le Kremlin-Bicêtre, FranceFaculté de Médecine Paris-SudUnité Mixte de Recherche-S1185, Univ Paris-Sud, Université Paris-Saclay, F-94276 Le Kremlin-Bicêtre, FranceInstitut National de la Santé et de la Recherche Médicale (INSERM) U1185F-94276 Le Kremlin-Bicêtre, FranceRheumatology DepartmentCochin University Hospital, Paris F75014, FranceClinical Chemistry DepartmentSart Tilman University Hospital, Liège, BelgiumNephrology and Dialysis DepartmentSart Tilman University Hospital, Liège, BelgiumAssistance Publique-Hôpitaux de ParisHôpital de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction and Centre de Référence des Maladies Endocriniennes Rares de la Croissance, F94275 Le Kremlin-Bicêtre, FranceUMR S1185Faculté de Médecine Paris-Sud, Univ Paris-Sud, Université Paris-Saclay, F-94276 Le Kremlin-Bicêtre, FranceINSERM U1185F-94276 Le Kremlin-Bicêtre, France Service des Explorations FonctionnellesNecker-Enfants Malades University Hospital, 149 Rue de Sèvres, Paris F75015, FranceHormonology LaboratoryPontchaillou University Hospital, Rennes F29000, FranceService de Génétique MoléculairePharmacogénétique et Hormonologie, F-94275 Le Kremlin-Bicêtre, FranceFaculté de Médecine Paris-SudUnité Mixte de Recherche-S1185, Univ Paris-Sud, Université Paris-Saclay, F-94276 Le Kremlin-Bicêtre, FranceInstitut National de la Santé et de la Recherche Médicale (INSERM) U1185F-94276 Le Kremlin-Bicêtre, FranceRheumatology DepartmentCochin University Hospital, Paris F75014, FranceClinical Chemistry DepartmentSart Tilman University Hospital, Liège, BelgiumNephrology and Dialysis DepartmentSart Tilman University Hospital, Liège, BelgiumAssistance Publique-Hôpita
Abstract
OBJECTIVE: To determine parathyroid hormone (PTH) reference values in French healthy adults, taking into account serum 25-hydroxyvitamin D (25OHD), renal function, age, gender, and BMI. PARTICIPANTS AND MAIN BIOLOGICAL MEASUREMENTS: We studied 898 healthy subjects (432 women) aged 18-89 years with a normal BMI and estimated glomerular filtration rate (eGFR), 81 patients with surgically proven primary hyperparathyroidism (PHPT), and 264 dialysis patients. 25OHD and third-generation PTH assays were implemented on the LIAISON XL platform. RESULTS: Median PTH and 25OHD values in the 898 healthy subjects were 18.8 ng/l and 23.6 ng/ml respectively. PTH was lower in subjects with 25OHD ≥30 ng/ml than in those with lower values. Among the 183 subjects with 25OHD ≥30 ng/ml, those aged ≥60 years (n=31) had higher PTH values than younger subjects, independent of 25OHD, BMI, and eGFR (P<0.001). Given the small number of subjects aged ≥60 years, we adopted the 95% CI of PTH values for the entire group of 183 vitamin D-replete subjects (9.4-28.9 ng/l) as our reference values. With 28.9 ng/l as the upper limit of normal (ULN) rather than the manufacturer's ULN of 38.4 ng/l, the percentage of PHPT patients with 'high' PTH values rose to 90.1% from 66.6% (P<0.001), and 18.6% of the dialysis patients were classified differently in view of the KDIGO target range (two to nine times the ULN). CONCLUSION: When only subjects with 25OHD ≥30 ng/ml were included in the reference population, the PTH ULN fell by 22.4%, diagnostic sensitivity for PHPT improved, and the classification of dialysis patients was modified.
OBJECTIVE: To determine parathyroid hormone (PTH) reference values in French healthy adults, taking into account serum 25-hydroxyvitamin D (25OHD), renal function, age, gender, and BMI. PARTICIPANTS AND MAIN BIOLOGICAL MEASUREMENTS: We studied 898 healthy subjects (432 women) aged 18-89 years with a normal BMI and estimated glomerular filtration rate (eGFR), 81 patients with surgically proven primary hyperparathyroidism (PHPT), and 264 dialysis patients. 25OHD and third-generation PTH assays were implemented on the LIAISON XL platform. RESULTS: Median PTH and 25OHD values in the 898 healthy subjects were 18.8 ng/l and 23.6 ng/ml respectively. PTH was lower in subjects with 25OHD ≥30 ng/ml than in those with lower values. Among the 183 subjects with 25OHD ≥30 ng/ml, those aged ≥60 years (n=31) had higher PTH values than younger subjects, independent of 25OHD, BMI, and eGFR (P<0.001). Given the small number of subjects aged ≥60 years, we adopted the 95% CI of PTH values for the entire group of 183 vitamin D-replete subjects (9.4-28.9 ng/l) as our reference values. With 28.9 ng/l as the upper limit of normal (ULN) rather than the manufacturer's ULN of 38.4 ng/l, the percentage of PHPT patients with 'high' PTH values rose to 90.1% from 66.6% (P<0.001), and 18.6% of the dialysis patients were classified differently in view of the KDIGO target range (two to nine times the ULN). CONCLUSION: When only subjects with 25OHD ≥30 ng/ml were included in the reference population, the PTH ULN fell by 22.4%, diagnostic sensitivity for PHPT improved, and the classification of dialysis patients was modified.